Retapamulin for Reducing MRSA Nasal Carriage
Methicillin-Resistant Staphylococcus Aureus
About this trial
This is an interventional prevention trial for Methicillin-Resistant Staphylococcus Aureus focused on measuring MRSA, MRSA resistant to mupirocin
Eligibility Criteria
Inclusion Criteria:
- 18 years of age or older
- Have a type of MRSA that is resistant to mupirocin (a drug used to treat MRSA)
Exclusion Criteria:
- Allergic to retapamulin
- Unable to use retapamulin via your nose (i.e. nose surgery, etc.)
- Are pregnant and/or breastfeeding
Sites / Locations
- University of California, Irivne
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Retapamulin
Placebo
Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of retapamulin with follow up bilateral nares swab one week following completion of therapy (~D12) to assess clearance. If follow up swabs are positive for MRSA, patients will be given a second course of the same agent (retapamulin) to begin one week following swab collection (~D19-23) so that up to two decolonization attempts will be made. A final set of bilateral nares swabs will be obtained from all subjects six weeks from the completion of initial treatment (~D47).
Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of a placebo with follow up bilateral nares swab one week following completion of therapy (~D12) to assess clearance. If follow up swabs are positive for MRSA, patients will be given a second course of the same agent (placebo) to begin one week following swab collection (~D19-23) so that up to two decolonization attempts will be made. A final set of bilateral nares swabs will be obtained from all subjects six weeks from the completion of initial treatment (~D47).